Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study

This trial investigated the tolerability and effect of modified citrus pectin (Pecta-Sol(R)) in 13 men with prostate cancer and biochemical prostate-specific antigen (PSA) failure after localized treatment, that is, radical prostatectomy, radiation, or cryosurgery. A total of 13 men were evaluated for tolerability and 10 for efficacy. Changes in the prostate-specific antigen doubling time (PSADT) of the 10 men were the primary end point in the study. We found that the PSADT increased (P-value < 0.05) in seven (70%) of 10 men after taking MCP for 12 months compared to before taking NICE This study suggests that MCP may lengthen the PSADT in men with recurrent prostate cancer.